Our top pick for
Building a portfolio
BridgeBio Pharma, Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 369 staff and has a trailing 12-month revenue of around USD$21.9 million.
|Latest market close||USD$56.86|
|52-week range||USD$14.23 - USD$70.56|
|50-day moving average||USD$52.7921|
|200-day moving average||USD$38.1195|
|Wall St. target price||USD$56.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.901|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-17.13%|
|1 month (2020-12-22)||-16.27%|
|3 months (2020-10-22)||41.41%|
|6 months (2020-07-22)||84.10%|
|1 year (2020-01-22)||66.45%|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
|Revenue TTM||USD$21.9 million|
|Gross profit TTM||USD$38.1 million|
|Return on assets TTM||-37.25%|
|Return on equity TTM||-122.43%|
|Market capitalisation||USD$8.5 billion|
TTM: trailing 12 months
There are currently 11.0 million BridgeBio Pharma shares held short by investors – that's known as BridgeBio Pharma's "short interest". This figure is 0% up from 11.0 million last month.
There are a few different ways that this level of interest in shorting BridgeBio Pharma shares can be evaluated.
BridgeBio Pharma's "short interest ratio" (SIR) is the quantity of BridgeBio Pharma shares currently shorted divided by the average quantity of BridgeBio Pharma shares traded daily (recently around 654689.50506857). BridgeBio Pharma's SIR currently stands at 16.77. In other words for every 100,000 BridgeBio Pharma shares traded daily on the market, roughly 16770 shares are currently held short.
However BridgeBio Pharma's short interest can also be evaluated against the total number of BridgeBio Pharma shares, or, against the total number of tradable BridgeBio Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BridgeBio Pharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 BridgeBio Pharma shares in existence, roughly 90 shares are currently held short) or 0.2141% of the tradable shares (for every 100,000 tradable BridgeBio Pharma shares, roughly 214 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BridgeBio Pharma.
Find out more about how you can short BridgeBio Pharma stock.
We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; collaboration with Salk Institute for Biological Studies; and Maze Therapeutics establishes a joint venture, Contour Therapeutics to advance precision medicine to treat cardiovascular diseases. The company was founded in 2015 and is headquartered in Palo Alto, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.